The four impacted products, which are intended to be sterile, are sold under the brand names Equate, CVS Health and AACE Pharmaceuticals, and have expiration dates ranging from February 2024 to ...

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...

Despite CVS Health's issues, its prospects and solid dividend program make it attractive for income seekers. Johnson & ...

CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. Read More on CVS: CVS Health NewsMORE Related Stocks Indices Commodities ...